2-甲氧基萘-1-甲胺 | 136402-93-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 中文名称: 2-甲氧基萘-1-甲胺
• 英文名称: 1-aminomethyl-2-methoxynaphthalene
• 英文别名: C-(2-methoxy-[1]naphthyl)-methylamine；1-Aminomethyl-2-methoxy-naphthalin；1-Aminomethyl-naphthol-(2)-methylaether；2-methoxynaphthylmethylamine；2-methoxynaphthylamine；(2-Methoxynaphthalen-1-yl)methanamine
• CAS: 136402-93-2
• 化学式: C₁₂H₁₃NO
• mdl: MFCD02327725
• 分子量: 187.241
• InChiKey: REAOSNBEURFYOE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  35.2
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 海关编码：
  2922299090

反应信息

• 作为反应物：
  描述：

  2-甲氧基萘-1-甲胺 在 盐酸 、 亚硝酸 、 苯 作用下， 生成 1-(氯甲基)-2-甲氧基萘
  参考文献：
  名称：

  Jacobs; Heidelberger, Journal of Biological Chemistry, 1915, vol. 20, p. 674

  摘要：

  DOI：
• 作为产物：
  描述：

  2-萘甲醚 在 盐酸 、 甲醇 、 sodium hydroxide 作用下， 生成 2-甲氧基萘-1-甲胺
  参考文献：
  名称：

  Amine Replacement Reactions of α-Dimethylaminomethyl-β-methoxynaphthalene

  摘要：

  DOI：

  10.1021/ja01171a083

文献信息

• Diazapane derivatives useful as antagonists of neurokinin 1 receptor and methods for their formation
  申请人：——

  公开号：US20020010174A1

  公开（公告）日：2002-01-24

  The invention relates to compounds of the formula 1 wherein R 1 , R 2 are independently from each other aryl or heteroaryl, wherein the heteroaryl group contains one or two heteroatoms, selected from N, O, or S, and wherein the aryl or heteroaryl groups are optionally substituted by 1 to 3 substituents, which are independently from each other halogen, CF 3 , lower alkoxy or lower alkyl; R 3 is hydrogen, lower alkyl, —(CH 2 ) n N(R) 2 , —(CH 2 ) n -heteroaryl or is a —(CH 2 ) n -non aromatic heterocycle, which heterocycles are optionally substituted by halogen, CF 3 , lower alkoxy or lower alkyl; R 4 is ═O, ═N(CH 2 ) n CH 3 or ═N(CH 2 ) n N(R) 2 ; R 3 and R 4 may be together with the N and C atoms to which they are attached the group —CR 5 ═N—N═; R 5 is hydrogen, —(CH 2 ) n N(R) 2 , —(CH 2 ) n -heteroaryl or is a —(CH 2 ) n -non aromatic heterocycle, which heterocycles are optionally substituted by halogen, CF 3 , lower alkoxy or lower alkyl; R is hydrogen or lower alkyl; n is 0, 1, 2 or 3; and pharmaceutically acceptable acid addition salts and enantiomeric forms thereof. The compounds are useful in the treatment of diseases, related to the NK-1 receptor.

  该发明涉及以下化合物的结构式1，其中R1、R2分别独立地为芳基或杂环芳基，其中杂环芳基含有一个或两个从N、O或S中选择的杂原子，而芳基或杂环芳基可选择地被1至3个取代基取代，这些取代基独立地为卤素、三氟甲基、低烷氧基或低烷基；R3为氢、低烷基、—(CH2)nN(R)2、—(CH2)n-杂环芳基或为—(CH2)n-非芳香杂环，这些杂环可选择地被卤素、三氟甲基、低烷氧基或低烷基取代；R4为HO、N(CH2)nCH3或N(CH2)nN(R)2；R3和R4可以与它们连接的N和C原子一起形成基团—CR5HN—NNH；R5为氢、—(CH2)nN(R)2、—(CH2)n-杂环芳基或为—(CH2)n-非芳香杂环，这些杂环可选择地被卤素、三氟甲基、低烷氧基或低烷基取代；R为氢或低烷基；n为0、1、2或3；以及其药学上可接受的酸盐和对映体形式。这些化合物在治疗与NK-1受体相关的疾病中是有用的。
• Arylalkylamine vanadium (V) salts for the treatment and/or prevention of Diabetes mellitus
  申请人：Exposito Royo Miriam

  公开号：US20070066682A1

  公开（公告）日：2007-03-22

  This invention provides compounds of formula (IIA) and pharmaceutical compositions thereof, where M, a, b, and R 1 -R 5 are as defined herein, for treating human type 1 and type 2 diabetes, particularly insulin-resistant diabetes. Pharmaceutical compositions comprising the compounds of formula (IIA) are also disclosed.

  该发明提供了公式（IIA）的化合物及其药物组成物，其中M、a、b和R1-R5如本文所定义，用于治疗人类1型和2型糖尿病，特别是胰岛素抵抗性糖尿病。还公开了包含公式（IIA）化合物的药物组成物。
• [EN] ARYLALKYLAMINE VANADIUM (V) SALTS FOR THE TREATMENT AND/OR PREVENTION OF DIABETES MELLITUS<br/>[FR] ARYLALKYLAMINE, SELS DE VANADIUM (V) POUR LE TRAITEMENT ET/OU LA PREVENTION DU DIABETE SUCRE
  申请人：GENMEDICA THERAPEUTICS SL

  公开号：WO2006003189A1

  公开（公告）日：2006-01-12

  This invention provides compounds and pharmaceutical compositions thereof for treating human type 1 and type 2 diabetes, particularly insulin-resistant diabetes.

  这项发明提供了用于治疗人类1型和2型糖尿病的化合物和药物组合物，特别是胰岛素抵抗性糖尿病。
• The synthesis and binding properties of bibracchial lariat ethers
  作者：Defen Wang、Yuhua Ge、Hongwen Hu、Kaibei Yu、Zhongyuan Zhou

  DOI：10.1039/c39910000685

  日期：——

  1-Aminomethyl-2-methoxynaphthalene was treated with polyethylene glycol diiodides in the presence of Li+, Na+ and K+ ions as template to produce the corresponding bibracchial lariat ether (BIBLE) complexes; the crystal structures of its sodium and potassium complexes are reported.

  以聚乙二醇二碘化物为模板，在Li +，Na +和K +离子的存在下，将1-氨基甲基-2-甲氧基萘处理成相应的双臂套索醚（BIBLE）配合物。据报道其钠和钾配合物的晶体结构。
• 3-SUBSTITUTED-5- AND 6-AMINOALKYL INDOLE-2-CARBOXYLIC ACID AMIDES AND RELATED ANALOGS AS INHIBITORS OF CASEIN KINASE I
  申请人：METZ, JR. William Arthur

  公开号：US20090082340A1

  公开（公告）日：2009-03-26

  The present invention discloses and claims methods for the treatment of a patient suffering from a disease or disorder ameliorated by inhibition of casein kinase Iε activity comprising the administration of a compounds of formula (I) and formula (II) as inhibitors of human casein kinase Iε, and methods of using said compounds of formula (I) and formula (II) for treating central nervous system diseases and disorders including mood disorders and sleep disorders. The R-group substituents are defined herein and pharmaceutical compositions comprising compounds of formula (I) or formula (II) useful in the claimed methods of treatment are also disclosed.

  本发明揭示和声明了治疗因抑制酪蛋白激酶Iε活性而改善的疾病或疾病患者的方法，包括给予公式（I）和公式（II）化合物作为人类酪蛋白激酶Iε的抑制剂，并使用公式（I）和公式（II）化合物治疗中枢神经系统疾病和疾病，包括情绪障碍和睡眠障碍的方法。本文中定义了R基取代基，还揭示了包含公式（I）或公式（II）化合物的制药组合物，可用于所声明的治疗方法。